Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: Impact of recipient/donor factors, transplant conditions and myelotoxic drugs

Haematologica

Volumn 96, Issue 12, 2011, Pages 1838-1845

  Nakamae, Hirohisa ^a,b   Storer, Barry ^a,c   Sandmaier, Brenda M ^a,c   Maloney, David G ^a,c   Davis, Chris ^a   Corey, Lawrence ^a,c   Storb, Rainer ^a,c   Boeckh, Michael ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytopenias after day 28; Ganciclovirrelated neutropenia; Non myeloablative allogeneic hematopoietic stem cell transplantation

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GANCICLOVIR; LEUKOCYTE ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; FEMALE; GRAFT RECIPIENT; HUMAN; INTERMETHOD COMPARISON; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROBABILITY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADULT; AGE FACTORS; AGED; ANEMIA; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUTROPENIA; THROMBOCYTOPENIA; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 82855172185     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.044966     Document Type: Article

References (28)

1. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90(6):2502-8.
2. Bittencourt H, Rocha V, Filion A, Ionescu I, Herr AL, Garnier F, et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies longterm responders. Bone Marrow Transplant. 2005;36(5):431-5.
3. Peralvo J, Bacigalupo A, Pittaluga PA, Occhini D, van Lint MT, Frassoni F, et al. Poor graft function associated with graftversus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant. 1987;2(3):279-85.
4. Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T. Association of specific cytomegalovirus (CMV) genotypes with death from myelosuppression after marrow transplantation. Blood. 1997;90(5):2097-102.
5. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(3):154-62.
6. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88(10): 4063-71.
7. Sommadossi JP, Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3- dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987;31(3):452-4.
8. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, et al. HLAmatched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102(6):2021-30.
9. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLAmatched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620-9.
10. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-400.
11. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, et al. Nonmyeloablative hematopoietic cell transplantation: replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci. 2001;938:328-37; discussion 337-9.
12. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104(12): 3535-42.
13. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23(16):3819-29.
14. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation (Review). Bone Marrow Transplant. 2001;27 (Suppl. 2):S13-S22.
15. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. In: Schechter GP, Broudy VC, Williams ME, eds. Hematology 2001: American Society of Hematology Education Program Book. Washington, DC: The American Society of Hematology; 2001:375-91.
16. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102(9):3447-54.
17. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20(1):128-35.
18. Boeckh M, Huang ML, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol. 2004;42 (3):1142-8.
19. Nakamae H, Kirby KA, Sandmaier BM, Norasetthada L, Maloney DG, Maris MB, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(6):694-703.
20. Boeckh M, Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23): 5711-9.
21. Sangiolo D, Storer B, Nash R, Corey L, Davis C, Flowers M, et al. Toxicity and efficacy of daily Dapsone as pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant. 2005;11(7):521-9.
22. Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc. 2008;40(3):752-4.
23. Thomas SE, Anderson S, Gordon KL, Oyama TT, Shankland SJ, Johnson RJ. Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. JJ Am Soc Nephrol. 1998;9(2):231-42.
24. Wang Z, Sorror ML, Leisenring W, Schoch G, Maloney DG, Sandmaier BM, et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative hematopoietic cell transplantation. Br J Haematol. 2010;149(1):101-10.
25. Dahl D, Hahn A, Koenecke C, Heuft HG, Dammann E, Stadler M, et al. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk. Transfusion. 2010;50(3):649-55.
26. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173-8.
27. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36(6):749-58.
28. Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112(1):219-27.